Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CD30biAb-AATC |
Synonyms | |
Therapy Description |
CD30biAb-AATC is a bispecific antibody that targets TNFRSF8 (CD30) and CD3, which potentially induces T-cell activation and cytotoxicity in CD30-expressing tumor cells (PMID: 37646042). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CD30biAb-AATC | CD3 Antibody 99 | CD30biAb-AATC is a bispecific antibody that targets TNFRSF8 (CD30) and CD3, which potentially induces T-cell activation and cytotoxicity in CD30-expressing tumor cells (PMID: 37646042). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05544968 | Phase Ib/II | CD30biAb-AATC | CD30biAb-AATC for CD30+ Malignancies | Not yet recruiting | USA | 0 |